ライフサイエンスコーパス: high-dose therapy

1 drug-tolerant cells is related to the use of high-dose therapy.

2 osensitive relapse are better candidates for high-dose therapy.

3 onse to the regimen given immediately before high-dose therapy.

4 chieved a partial response before undergoing high-dose therapy.

5 of 61 months (range, 40 to 139 months) after high-dose therapy.

6 at risk for early toxic mortality following high-dose therapy.

7 x 10(5)/kg GM-CFC; 22 patients proceeded to high-dose therapy.

8 transplant into high-risk patients following high-dose therapy.

9 ies failed to show a definitive advantage to high-dose therapy.

10 ion-free survival and overall survival after high-dose therapy.

11 lenalidomide predicts a poorer outcome after high-dose therapy.

12 rticularly suited for older adults requiring high-dose therapy.

13 ing problem that occurs not only in those on high-dose therapy.

14 mor effects independent of the action of the high-dose therapy.

15 n unequivocal benefit for consolidation with high-dose therapy.

16 eligible for the triple-tandem consolidation high-dose therapy.

17 ration and treatment with either low-dose or high-dose therapy.

18 s largely incurable despite conventional and high-dose therapies.

19 nts who were in or near CR before undergoing high-dose therapy, 14 remain continuously progression-fr

20 ation (59%) led to an improved CR rate after high-dose therapy (41.2% vs 20.0%; P = .02), translating

21 169 (79%) of 214 patients receiving high-dose therapy and 142 (68%) of 205 patients on low-d

22 successfully treated with the combination of high-dose therapy and AHSCT, confirming the efficacy of

23 onventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant

24 These results suggest that high-dose therapy and ASCT during first remission may im

25 The results of high-dose therapy and ASCT for patients with relapsed di

26 High-dose therapy and ASCT is an effective treatment str

27 Responses to high-dose therapy and ASCT were complete response (30%),

28 A prospective randomized study comparing high-dose therapy and ASCT with conventional chemotherap

29 tion/maintenance protocol (CC) or to receive high-dose therapy and ASCT.

30 Our results confirm the efficacy of high-dose therapy and autografting in recurrent or refra

31 atched patients demonstrate an advantage for high-dose therapy and autografting in the sustained cont

32 come ultimate determinants of the success of high-dose therapy and autografting.

33 colony-stimulating factor (GM-CSF) following high-dose therapy and autologous bone marrow transplant

34 ted a pilot study to investigate the role of high-dose therapy and autologous bone marrow/stem cell t

35 failure-free survival is possible following high-dose therapy and autologous hematopoietic rescue fo

36 ble patients to proceed toward consolidative high-dose therapy and autologous stem cell rescue with i

37 tezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantati

38 ively treated by R-ICE or R-DHAP followed by high-dose therapy and autologous stem cell transplantati

39 with disseminated POEMS can be treated with high-dose therapy and autologous stem cell transplantati

40 High-dose therapy and autologous stem cell transplantati

41 mide-dexamethasone (VCD) as induction before high-dose therapy and autologous stem cell transplantati

42 hes both in older patients, not eligible for high-dose therapy and autologous stem cell transplantati

43 y to be cured by treatment with conventional high-dose therapy and autologous stem cell transplantati

44 linical trials established the importance of high-dose therapy and autologous stem-cell rescue and hi

45 lymphoma should be seriously considered for high-dose therapy and autologous stem-cell support.

46 of the strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant (H

47 Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantati

48 The role for high-dose therapy and autologous stem-cell transplantati

49 (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantati

50 t they are often denied potentially curative high-dose therapy and autologous stem-cell transplantati

51 e, one to five); six patients relapsed after high-dose therapy and autologous stem-cell transplantati

52 ith either conventional-dose chemotherapy or high-dose therapy and autologous stem-cell transplantati

53 is uncertain whether cures are possible with high-dose therapy and bone marrow transplant from a huma

54 ersistence of minimal residual disease after high-dose therapy and either allogeneic or autologous st

55 nd normal cytogenetics, who received uniform high-dose therapy and found FLT3 ITD in 23 (28%) patient

56 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transpl

57 ts were able to complete all three cycles of high-dose therapy and peripheral-blood stem-cell rescue,

58 Outcome from high-dose therapy and significant prognostic factors wer

59 Seventy of these patients received high-dose therapy and stem-cell transplantation in first

60 ly diagnosed patients who went on to receive high-dose therapy and tandem stem cell transplants.

61 ake strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is fe

62 he rationale, methods, and recent results of high-dose therapy and the questions that it raises.

63 Stratification by low-dose or high-dose therapy and the use of concurrent aspirin was

64 tes are much higher for patients who receive high-dose therapy and transplantation.

65 89 high-risk breast cancer patients received high-dose therapy and were randomized to receive an auto

66 tins in CABG patients, including the role of high-dose therapy, and highlight areas for future study.

67 relapsed disease have improved survival with high-dose therapy, and those with high-risk disease may

68 uximab and high-dose cytarabine, followed by high-dose therapy appears quite promising.

69 Further development of new high-dose therapy approaches has led to a reduction in t

70 ions remain in terms of the proper timing of high-dose therapy, appropriate stratification by risk fa

71 outcomes, and increased nephrotoxicity with high-dose therapy are challenging its current role as fi

72 The use of high-dose therapy at relapse, a longer duration of remis

73 , doxorubicin, vincristine, and prednisone + high-dose therapy/autologous stem cell rescue), RHCVAD+H

74 achievement of complete response (CR) after high-dose therapy/autologous stem cell transplantation (

75 The incorporation of high-dose therapy/autologous stem cell transplantation (

76 of FISH testing in 238 patients who received high-dose therapy between January 1990 and September 200

77 g within 1 year benefited significantly from high-dose therapy by all outcome measures (OS, EFS, FFP)

78 This effect has been emphasized over high-dose therapy by using less intensive, and therefore

79 sing 131I-anti-CD20 (n = 27) or conventional high-dose therapy (C-HDT) (n = 98) and autologous hemato

80 ears follow-up favored patients who received high-dose therapy compared with conventional salvage tre

81 High-dose therapy consisted of fractionated total-body i

82 Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation.

83 The controversy over high-dose therapy continues, and its role in the managem

84 onors underwent an allograft as their second high-dose therapy cycle.

85 It has become clear, however, that the high dose therapy does not eradicate the malignancy in m

86 Nonetheless, high-dose therapy does appear feasible and may offer cur

87 We conclude that high-dose therapy followed by allo-SCT from related or u

88 This study evaluated the results of high-dose therapy followed by autologous bone marrow or

89 r refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic p

90 High-dose therapy followed by autologous stem-cell trans

91 patients with multiple myeloma treated with high-dose therapy followed by hematopoietic stem cell tr

92 We conclude that high-dose therapy followed by transplantation from a HLA

93 e a more significant advance in the field of high-dose therapy for multiple sclerosis.

94 When incorporated into high-dose therapy for myeloma, thalidomide increased the

95 er studies are helping to define the role of high-dose therapy for patients with Hodgkin's lymphoma,

96 Before consideration of high-dose therapy for recurrent/persistent advanced ovar

97 However, neither low-dose nor high-dose therapy had an effect on insulin-mediated supp

98 isease who attained complete remission after high-dose therapy had the best outcome, with an OS at 5

99 High-dose therapy has been used in progressive multiple

100 of novel therapies and the increased use of high-dose therapy have translated into better outcome fo

101 A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow trans

102 we evaluated its efficacy and toxicity after high-dose therapy (HDT) and autologous hematopoietic cel

103 ) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transpl

104 High-dose therapy (HDT) and autologous stem-cell transpl

105 that autologous hematopoietic cell-supported high-dose therapy (HDT) effected higher complete respons

106 High-dose therapy (HDT) has increased complete remission

107 vide superior outcome to standard treatment, high-dose therapy (HDT) has usually been limited to pati

108 (ESFT) is poor, and the relative benefit of high-dose therapy (HDT) is controversial.

109 ith malignant lymphoma who were eligible for high-dose therapy (HDT) were enrolled onto the trial.

110 oietic colony-stimulating factors (CSFs), or high-dose therapy (HDT) with autologous bone marrow supp

111 or MM restaging in 3,077 patients undergoing high-dose therapy (HDT).

112 th metastatic NB had favorable outcomes with high-dose therapy if their tumors were hyperdiploid and

113 rther elucidate the role of radiotherapy and high-dose therapy in Hodgkin's disease and the non-Hodgk

114 ingle institution comparing conventional and high-dose therapy in matched patients demonstrate an adv

115 Although dose-intensive strategies or high-dose therapy induction followed by autologous stem-

116 f PCR-detectable MRD after BMT suggests that high-dose therapy may contribute to improved outcome in

117 High-dose therapy may eventually become the standard for

118 ic outcomes, such as dosimetric estimations, high-dose therapies, multiple fractionated administratio

119 Future trials of high-dose therapy must define rigorous eligibility crite

120 Despite an increasing use of high-dose therapy of i.v. gammaglobulin (IVIg) in the tr

121 High-dose therapy of imatinib was beneficial for patient

122 n 1 x 10(6)/kg CD34+ cells are infused after high-dose therapy, particularly with GM-CFC less than 1

123 For high-dose therapy patients, -17(p13) and t(4;14) have cl

124 Three to 7 months after high-dose therapy, patients received a series of monthly

125 d 3-fold lower than the mean AD for low- and high-dose therapy, respectively.

126 mide-doxorubicin-vincristine-prednisone with high-dose therapy/stem-cell support prolongs remission a

127 Long-term follow-up on high-dose therapy suggests a potential role for this mod

128 with less than 1 x 10(5)/kg GM-CFC received high-dose therapy supported by bone marrow collected aft

129 After high-dose therapy, the estimates of absorbed dose to the

130 on graft-versus-leukemia effects rather than high-dose therapy to eliminate malignant cells.

131 Mastectomy was performed after high-dose therapy to evaluate pathologic response to tre

132 a, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabin

133 ries of induction regimens and two cycles of high-dose therapy ("Total Therapy").

134 lmonary metastases 3 months after completing high-dose therapy, underwent complete resection of lung

135 isease evident on neuroimaging then received high-dose therapy using carmustine, etoposide, cytarabin

136 assessments supported the superiority of the high-dose therapy vs placebo.

137 ine and taxane therapy; cisplatin as part of high-dose therapy was allowed.

138 e use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase

139 The protective effect of short-course, high-dose therapy was stronger in households with 3 or m

140 Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respe

141 esult, the trial was stopped and patients on high-dose therapy were crossed over to low-dose therapy.

142 py with anthracyclines and taxanes and prior high-dose therapy, were allowed.

143 n an effort to augment B cell recovery after high dose therapy with hematopoietic reconstitution.

144 This review evaluates the results of high dose therapy with stem cell reconstitution used to

145 High-dose therapy with allogeneic hematopoietic cell tra

146 High-dose therapy with autologous and allogeneic bone ma

147 ates that breast cancer patients who receive high-dose therapy with autologous CD34(+) marrow support

148 (32%) had progressive disease after previous high-dose therapy with autologous HCT.

149 nting paraprotein, in 550 patients receiving high-dose therapy with autologous hematopoietic cell tra

150 Some subjects who receive high-dose therapy with autologous hematopoietic progenit

151 High-dose therapy with autologous hematopoietic progenit

152 High-dose therapy with autologous peripheral blood stem

153 The upper age limit of high-dose therapy with autologous progenitor-cell and/ o

154 Seven patients received high-dose therapy with autologous stem cell support, 3 o

155 High-dose therapy with autologous stem cell transplantat

156 Early trials of high-dose therapy with autologous stem cell transplantat

157 High-dose therapy with autologous stem-cell rescue is an

158 ho are eligible for and those ineligible for high-dose therapy with autologous stem-cell transplantat

159 High-dose therapy with autologous stem-cell transplantat

160 High-dose therapy with melphalan 200 mg/m(2) is feasible

161 High-dose therapy with melphalan can prolong survival am

162 less than 1 x 10(5)/kg GM-CFC, six received high-dose therapy with PBSC alone and five had delayed e

163 treatment of multiple myeloma, particularly high-dose therapy with peripheral blood stem cell transp

164 likely to relapse following three cycles of high-dose therapy with peripheral blood stem-cell rescue

165 egimen and consolidated with three cycles of high-dose therapy with peripheral blood stem-cell rescue

166 ients then underwent triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue

167 Patients with low-grade lymphoma who receive high-dose therapy with stem cell support appear to have

168 s, administered alone or in combination, and high-dose therapy with stem cell transplant.

169 High-dose therapy with supporting autologous stem-cell t

170 High-dose therapy with tandem autologous stem-cell rescu

171 of the reductive pentosephosphate pathway by high-dose therapy with thiamine and the thiamine monopho

172 tandem high-dose, myeloablative treatments (high-dose therapy) with stem-cell rescue (HDT/SCR) in ra

173 efractory' conditions have been treated with high-dose therapy, with or without autologous stem cell

174 High-dose therapy, without or with stem cell transplanta

175 e myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do c